Preferred Label : Fingolimod Hydrochloride;
MeSH definition : A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and
homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE
1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.;
MeSH synonym : 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride;
CISMeF synonym : Hydrochloride, Fingolimod;
MeSH Hyperonym : fingolimod;
MeSH hyponym : FTY-720; gilenya; FTY 720; FTY720; Gilenia;
MeSH Related Number : 162359-56-0 (fingolimod hydrochloride); 3QN8BYN5QF;
Is substance : O;
UNII : G926EC510T;
Origin ID : D000068876;
UMLS CUI : C0388087;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Exact mapping(s) to DCI
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and
homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE
1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
https://ansm.sante.fr/tableau-marr/fingolimod
2025
false
false
false
France
French
guidelines for drug use
patient education handout
Fingolimod Hydrochloride
pregnancy
administration, oral
immunosuppressive agents
immunosuppressive agents
fingolimod
continuity of patient care
Fingolimod Hydrochloride
teratogens
multiple sclerosis, relapsing-remitting
breast feeding
Fingolimod Hydrochloride
risk management
---
https://www.ema.europa.eu/en/medicines/human/EPAR/fingolimod-mylan
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drugs, generic
Fingolimod Hydrochloride
Fingolimod Hydrochloride
administration, oral
multiple sclerosis, relapsing-remitting
adult
child
adolescent
fingolimod
drug interactions
contraception
pregnancy
breast feeding
abnormalities, drug-induced
teratogens
drug evaluation, preclinical
Sphingosine 1 Phosphate Receptor Modulators
Sphingosine 1 Phosphate Receptor Modulators
---
GILENYA (fingolimod) - Risk of Liver Injury
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2021/74803a-fra.php
2021
false
false
false
Canada
French
English
pharmacovigilance note
Chemical and Drug Induced Liver Injury
Fingolimod Hydrochloride
fingolimod
administration, oral
immunosuppressive agents
drug monitoring
guidelines for drug use
continuity of patient care
liver function tests
liver failure, acute
---
https://www.has-sante.fr/jcms/p_3266944/fr/gilenya-fingolimod
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
fingolimod
adult
child
adolescent
multiple sclerosis, relapsing-remitting
pregnancy
abnormalities, drug-induced
teratogens
fingolimod
fingolimod
Chemical and Drug Induced Liver Injury
liver failure, acute
evaluation of the transparency committee
fingolimod
Fingolimod Hydrochloride
Fingolimod Hydrochloride
Fingolimod Hydrochloride
---
https://ansm.sante.fr/informations-de-securite/gilenya-r-fingolimod-mise-a-jour-des-recommandations-afin-de-reduire-lede-reduction-du-risque-datteinte-hepatique-medicamenteuse
2020
false
false
false
France
French
guidelines for drug use
Chemical and Drug Induced Liver Injury
Fingolimod Hydrochloride
continuity of patient care
drug monitoring
liver function tests
immunosuppressive agents
fingolimod
Chemical and Drug Induced Liver Injury
hepatic insufficiency
acute disease
---
https://www.ema.europa.eu/en/medicines/human/EPAR/fingolimod-accord
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drugs, generic
fingolimod
fingolimod
fingolimod
immunosuppressive agents
immunosuppressive agents
multiple sclerosis, relapsing-remitting
adult
child
adolescent
aged
administration, oral
continuity of patient care
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fingolimod Hydrochloride
Fingolimod Hydrochloride
---
https://www.has-sante.fr/portail/jcms/c_2913088/fr/gilenya
2019
false
true
false
false
France
administration, oral
child
adolescent
treatment outcome
fingolimod
immunosuppressive agents
multiple sclerosis, relapsing-remitting
insurance, health, reimbursement
fingolimod
Fingolimod Hydrochloride
Fingolimod Hydrochloride
evaluation of the transparency committee
Fingolimod Hydrochloride
---
https://ansm.sante.fr/informations-de-securite/gilenya-r-fingolimod-nouvelle-contre-indication-chez-la-femme-enceinte-et-en-age-de-procreer-nutilisant-pas-une-contraception-efficace
2019
false
false
false
France
French
Fingolimod Hydrochloride
pregnancy
pharmacovigilance note
Female of child bearing age (finding)
abnormalities, drug-induced
fingolimod
contraception
multiple sclerosis, relapsing-remitting
administration, oral
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71921a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
Fingolimod Hydrochloride
immunosuppressive agents
pregnancy
Contraindications, Drug
abnormalities, drug-induced
fingolimod
guidelines for drug use
---
https://www.has-sante.fr/portail/jcms/c_2877323/fr/gilenya
2018
false
false
false
France
Fingolimod Hydrochloride
multiple sclerosis, relapsing-remitting
fingolimod
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2755878/fr/gilenya
2017
true
France
French
evaluation of the transparency committee
Fingolimod Hydrochloride
immunosuppressive agents
administration, oral
insurance, health, reimbursement
fingolimod
multiple sclerosis, relapsing-remitting
treatment outcome
---
https://www.cochrane.org/fr/CD009371/le-fingolimod-pour-la-sclerose-en-plaques-recurrente-remittente
2016
false
false
false
false
France
United Kingdom
Fingolimod Hydrochloride
Fingolimod Hydrochloride
review of literature
french abstract
fingolimod
multiple sclerosis, relapsing-remitting
Fingolimod Hydrochloride
---
Summary Safety Review - GILENYA (fingolimod) - Assessing the Risk of the Abnormal
Tissue Growth (Cancer)
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/gilenya3-fra.php
2016
false
false
false
Canada
French
English
drug evaluation
multiple sclerosis, relapsing-remitting
fingolimod
neoplasms
canada
risk assessment
Fingolimod Hydrochloride
---
Summary Safety Review - GILENYA (fingolimod) - Assessing the Potential Risk of a Rare
Brain Infection (Progressive Multifocal Leukoencephalopathy)
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/gilenya2-fra.php
2016
false
false
false
Canada
French
English
drug evaluation
pharmacovigilance note
leukoencephalopathy, progressive multifocal
Fingolimod Hydrochloride
administration, oral
fingolimod
immunosuppressive agents
risk assessment
multiple sclerosis, relapsing-remitting
adult
---
http://www.has-sante.fr/portail/jcms/c_2639636/fr/gilenya
2016
true
France
French
evaluation of the transparency committee
Fingolimod Hydrochloride
Fingolimod Hydrochloride
administration, oral
insurance, health, reimbursement
fingolimod
multiple sclerosis, relapsing-remitting
treatment outcome
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55160a-fra.php
2015
false
false
false
Canada
French
pharmacovigilance note
multiple sclerosis, relapsing-remitting
fingolimod
immunosuppressive agents
lymphoma
skin neoplasms
leukoencephalopathy, progressive multifocal
patients guideline
guidelines for drug use
continuity of patient care
mass screening
carcinoma, basal cell
Fingolimod Hydrochloride
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2014.01753/
2014
false
Switzerland
French
multiple sclerosis
journal article
immunosuppressive agents
immunosuppressive agents
bradycardia
atrioventricular block
algorithms
bradycardia
atrioventricular block
consensus
Drug-induced bradycardia (disorder)
Cardiotoxicity
Fingolimod Hydrochloride
Fingolimod Hydrochloride
---
https://www.revmed.ch/RMS/2013/RMS-384/Traitement-de-la-sclerose-en-plaques-nouveautes-et-complications
2013
true
Switzerland
French
multiple sclerosis
journal article
immunosuppressive agents
immunologic factors
Fingolimod Hydrochloride
Natalizumab
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14794a-fra.php
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14795a-fra.php
2012
false
Canada
French
English
guidelines for drug use
pharmacovigilance note
Fingolimod Hydrochloride
Fingolimod Hydrochloride
Fingolimod Hydrochloride
Contraindications, Procedure
immunosuppressive agents
fingolimod
multiple sclerosis
cardiovascular diseases
continuity of patient care
adult
immunosuppressive agents
Phlebitis of leg superficial
Contraindications, Drug
---
https://www.ema.europa.eu/medicines/human/EPAR/Gilenya
2012
false
United Kingdom
French
English
syndication feed
Fingolimod Hydrochloride
Fingolimod Hydrochloride
fingolimod
immunosuppressive agents
immunosuppressive agents
multiple sclerosis, relapsing-remitting
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
summary of product characteristics
package leaflet
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13645a-fra.php
2012
false
Canada
French
English
pharmacovigilance note
Cardiotoxicity
Fingolimod Hydrochloride
risk assessment
administration, oral
multiple sclerosis, relapsing-remitting
immunosuppressive agents
fingolimod
continuity of patient care
heart diseases
---
http://www.has-sante.fr/portail/jcms/c_1084362/gilenya
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-08/gilenya_-_ct-10252.pdf
2011
false
France
French
evaluation of the transparency committee
Fingolimod Hydrochloride
Fingolimod Hydrochloride
administration, oral
insurance, health, reimbursement
fingolimod
multiple sclerosis, relapsing-remitting
treatment outcome
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00067
2011
false
Canada
English
French
Fingolimod Hydrochloride
Fingolimod Hydrochloride
drug approval
canada
fingolimod
immunosuppressive agents
receptors, lysosphingolipid
adult
multiple sclerosis, relapsing-remitting
administration, oral
continuity of patient care
drug information
---
http://www.has-sante.fr/portail/jcms/c_1121524/gilenya-fingolimod-modulateur-des-recepteurs-a-la-sphingosine-1-phosphate-synthese-d-avis
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Fingolimod Hydrochloride
Fingolimod Hydrochloride
fingolimod
propylene glycols
immunosuppressive agents
multiple sclerosis, relapsing-remitting
administration, oral
insurance, health, reimbursement
S1PR1 protein, human
treatment outcome
receptors, lysosphingolipid
propylene glycols
---